Effect of Multispecies Probiotic Supplementation on Irritable Bowel Syndrome
Journal of Pharmaceutical Research International,
Page 1-9
DOI:
10.9734/jpri/2019/v28i630221
Abstract
Background: Irritable bowel syndrome (IBS) is a common, chronic and sometimes disabling functional disorder of the gastrointestinal system and its treatment remains as health problem. Thus the aim of this study was to evaluate the Effect of multispecies probiotic supplementation, as a novel and Controversial therapeutic method on Irritable bowel syndrome.
Materials and Methods: In this randomized double blind Placebo-controlled clinical trial, 60 patients with IBS were enrolled. The patients were divided randomly into two groups. Patients in intervention group received two 500 mg probiotic capsules (Familact®) and in control group, received two 500 mg placebo capsules daily for 30 consecutive days. The symptoms and quality of life were measured and compared at the beginning and just after the end of study for each case.
Results: Results showed the mean score of Abdominal pain after 1 month of treatment in the probiotic group was significantly lower than the control group (1.76 ± 2.04 vs. 2.88 ± 2.25, P=0.049, respectively). While, other symptoms and quality of life did not change significantly (P>0.05). Furthermore, defecation habit and global symptoms improvement was similar after intervention in both groups and we did not observe significant differences in these items (P>0.05).
Conclusion: The results of this study showed the beneficial effects of multispecies probiotic supplementation in controlling IBS patients’ abdominal pain. thus it can be prescribed as a therapeutic option in addition to standard therapy and significantly lead to better control of this symptom in the short term.
Keywords:
- Irritable bowel syndrome
- multispecies probiotic
- abdominal pain
- IBS symptoms
- quality of life.
How to Cite
References
Owyang C. Irritable bowel syndrome. In: Jameson JL, Kasper D, Longo D, Fauci A, Hauser S, Loscalzo J. Harrison's principles of internal medicine. 20th ed. New York: McGraw-Hill Education. 2018;2276-82.
Han SH, Lee OY, Bae SC, Lee SH, Chang YK, Yang SY, et al. Prevalence of irritable bowel syndrome in Korea: population-based survey using the Rome II criteria. J Gastroenterol Hepatol. 2006;21:1687–92.
Spiegel BM. Burden of illness in irritable bowel syndrome: looking beyond the patient. Clin Gastroenterol Hepatol. 2013; 11:156–7
Yu HB, Dai L, Zhou L, et al. An epidemiologic study of irritable bowel syndrome among officers and soilders in a Chinese air force. Chinese Journal of Gastroenterology and Hepatology. 2015;24 (11):1393–1396.
Liu CB, Liang G, Zheng QF, et al. Prevalence of and risk factors for irritable bowel syndrome in community residents in nanning. World Chinese Journal of Digestology. 2014;22(34):5365–5370.
Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: A clinical review. JAMA. 2015;313(9):949–958.
David L, Babin A, Picos A, Dumitrascu DL. Small intestinal bacterial overgrowth is associated with intestinal inflammation in the irritable bowel syndrome. Clujul Medical. 2014;87(3):163–165.
Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review. Am J Gastroenterol. 2009;104:1033–49.
McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008;14:2650–61.
Lee SH, Joo NS, Kim KM, Kim KN. The therapeutic effect of a multistrain probiotic on diarrhea-predominant irritable bowel syndrome: A pilot study. Gastroenterology research and practice; 2018.
Andrae DA1, Patrick DL, Drossman DA, Covington PS. Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients. Health Qual Life Outcomes. 2013;11:208.
Masaeli, N, Kheirabadi GR, Afshar H, Daghaghzadeh H, Maracy MR, Assadolahi FDWHPHK, Adibi P. Validity, reliability, and factor analysis of Persian version of quality of life questionnaire for irritable bowel syndrome (IBS-QOL-34). Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2013;18(6):492.
Plaza-Diaz J, Gomez-Llorente C, Fontana L, Gil A. Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics. World journal of gastroenterology: WJG. 2014;20(42): 15632–15649.
Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double‐blind, placebo‐ controlled trial. Journal of Gastroenterology and Hepatology. 2014;29(1):52-59.
McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World journal of gastroenterology: WJG. 2008;14(17): 2650.
Gawrońska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double‐ blind placebo‐controlled trial of Lactobacillus GG for abdominal pain disorders in children. Alimentary Pharmacology & Therapeutics. 2007;25(2):177-184.
Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life––a double‐blind, placebo‐controlled study. Alimentary Pharmacology & Therapeutics. 2011;33(10):1123-1132.
Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt L. J, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325-332.
Yoon JS1, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, Yoon BC, Choi HS, Chung WS, Seo JG. Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 2014;29(1):52-9.
Mezzasalma V, Manfrini E, Ferri E, Sandionigi A, La Ferla B, Schiano I, Di Gennaro P. A randomized, double-blind, placebo-controlled trial: The efficacy of multispecies probiotic supplementation in alleviating symptoms of irritable bowel syndrome associated with constipation. BioMed research international; 2016.
Yoon H, Park YS, Lee DH, Seo JG, Shin CM, Kim N. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. Journal of clinical biochemistry and nutrition. 2015;57(2):129-34.
Pourfarzi F, Enteshari Mogaddam A, Yazdanbod A, Tazakkori Z, Farzaneh E, Mirzarahimi M. The effect of probiotic yogurt on controlling the symptoms of irritable bowel syndrome. Journal of Ardabil University of Medical Sciences. 2011;11(1):24-32.
Shavakhi A, Minakari M, Farzamnia S, Peykar MS, Taghipour G, Tayebi A, et al. The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Advanced Biomedical Research. 2014;3.
-
Abstract View: 1675 times
PDF Download: 570 times
